دورية أكاديمية
أعرض في EDS

Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1.

التفاصيل البيبلوغرافية
العنوان: Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1.
المؤلفون: Døssing KB; Center for Genomic Medicine, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. kristina@doessing.dk., Binderup T; Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. ulrich.knigge@rh.regionh.dk., Kaczkowski B; The Bioinformatics Center, Department of Biology and Biotech and Research Innovation Centre, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark. b.kaczkowski@gmail.com., Jacobsen A; The Bioinformatics Center, Department of Biology and Biotech and Research Innovation Centre, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark. andersmbj@gmail.com., Rossing M; Center for Genomic Medicine, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. maria.rossing@rh.regionh.dk., Winther O; DTU Informatics, Technical University of Denmark, Anker Engelunds Vej 1, 2800 Kongens Lyngby, Denmark. ole.winther@gmail.com., Federspiel B; Department of Pathology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. birgitte.federspiel@rh.regionh.dk., Knigge U; Cluster for Molecular Imaging, Faculty of Health Sciences, Blegdamsvej 3B, 2100 Copenhagen, Denmark. ulrich.knigge@rh.regionh.dk., Kjær A; Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. ulrich.knigge@rh.regionh.dk., Friis-Hansen L; Center for Genomic Medicine, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. lejf@regionsjaelland.dk.
المصدر: Genes [Genes (Basel)] 2014 Dec 24; Vol. 6 (1), pp. 1-21. Date of Electronic Publication: 2014 Dec 24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101551097 Publication Model: Electronic Cited Medium: Print ISSN: 2073-4425 (Print) Linking ISSN: 20734425 NLM ISO Abbreviation: Genes (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel : MDPI
مستخلص: Expression of miRNAs in Neuroendocrine Neoplasms (NEN) is poorly characterized. We therefore wanted to examine the miRNA expression in Neuroendocrine Tumors (NETs), and identify their targets and importance in NET carcinogenesis. miRNA expression in six NEN primary tumors, six NEN metastases and four normal intestinal tissues was characterized using miRNA arrays, and validated by in-situ hybridization and qPCR. Among the down-regulated miRNAs miR-129-5p and the let-7f/let-7 family, were selected for further characterization. Transfection of miR-129-5p inhibited growth of a pulmonary and an intestinal carcinoid cell line. Analysis of mRNA expression changes identified EGR1 and G3BP1 as miR-129-5p targets. They were validated by luciferase assay and western blotting, and found robustly expressed in NETs by immunohistochemistry. Knockdown of EGR1 and G3BP1 mimicked the growth inhibition induced by miR-129-5p. let-7 overexpression inhibited growth of carcinoid cell lines, and let-7 inhibition increased protein content of the transcription factor BACH1 and its targets MMP1 and HMGA2, all known to promote bone metastases. Immunohistochemistry analysis revealed that let-7 targets are highly expressed in NETs and metastases. We found down-regulation of miR-129-5p and the let-7 family, and identified new neuroendocrine specific targets for these miRNAs, which contributes to the growth and metastatic potential of these tumors.
References: RNA. 2008 May;14(5):844-52. (PMID: 18375788)
Nature. 2010 Aug 12;466(7308):835-40. (PMID: 20703300)
Methods Mol Biol. 2011;740:33-43. (PMID: 21468966)
Am J Clin Pathol. 2005 Feb;123(2):256-60. (PMID: 15842051)
Cancer Res. 2009 Jun 1;69(11):4851-60. (PMID: 19487295)
Histochem J. 2002 May;34(5):223-31. (PMID: 12587999)
J Clin Oncol. 2008 Jun 20;26(18):3063-72. (PMID: 18565894)
Genes Cancer. 2011 Mar;2(3):288-97. (PMID: 21779499)
PLoS One. 2010 Jan 21;5(1):e8836. (PMID: 20098684)
Mol Cell Biol. 2005 Oct;25(19):8703-16. (PMID: 16166649)
EMBO J. 2009 Feb 18;28(4):347-58. (PMID: 19153603)
Int J Cancer. 2011 Dec 1;129(11):2600-10. (PMID: 21960261)
FEBS J. 2010 Feb;277(3):627-41. (PMID: 19968858)
Endocr Relat Cancer. 2011 Jul 11;18(4):479-89. (PMID: 21636701)
Endocr Relat Cancer. 2011 Oct 17;18 Suppl 1:S1-16. (PMID: 22005112)
Mol Cell. 2007 Jul 6;27(1):91-105. (PMID: 17612493)
Neuroendocrinology. 2006;84(1):42-8. (PMID: 17047316)
Biochem J. 2003 Aug 1;373(Pt 3):739-46. (PMID: 12755686)
Pathol Int. 2010 Apr;60(4):268-77. (PMID: 20403028)
Toxicol In Vitro. 2013 Aug;27(5):1589-95. (PMID: 22954529)
Cell Res. 2008 May;18(5):549-57. (PMID: 18379589)
Oncol Lett. 2012 May;3(5):1105-1108. (PMID: 22783400)
Trends Cell Biol. 2008 Oct;18(10):505-16. (PMID: 18774294)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Cancer Prev Res (Phila). 2010 May;3(5):670-9. (PMID: 20424128)
Genome Biol. 2004;5(10):R80. (PMID: 15461798)
Cancer Res. 2011 Jun 15;71(12):4260-8. (PMID: 21512136)
PLoS One. 2011 Apr 18;6(4):e18409. (PMID: 21533124)
Biol Cell. 2008 Feb;100(2):71-81. (PMID: 18199046)
Neuroendocrinology. 2007;85(1):45-53. (PMID: 17341847)
Clin Cancer Res. 2007 Aug 15;13(16):4704-12. (PMID: 17699847)
Methods. 2010 Dec;52(4):375-81. (PMID: 20621190)
Br J Cancer. 2009 Feb 10;100(3):501-10. (PMID: 19156147)
Cell Death Dis. 2013 Jun 06;4:e659. (PMID: 23744359)
Nat Rev Cancer. 2006 Apr;6(4):259-69. (PMID: 16557279)
Clin Cancer Res. 2009 May 15;15(10):3315-24. (PMID: 19447869)
PLoS One. 2011 Feb 11;6(2):e17167. (PMID: 21347261)
Methods Mol Biol. 2011;698:419-29. (PMID: 21431535)
Future Oncol. 2009 Sep;5(7):993-1003. (PMID: 19792968)
Nat Med. 2008 Dec;14(12):1319-20. (PMID: 19057557)
Cell. 2004 Mar 19;116(6):855-67. (PMID: 15035987)
Cancer Gene Ther. 2006 Feb;13(2):115-24. (PMID: 16138117)
Chromosoma. 2009 Aug;118(4):405-18. (PMID: 19340450)
Genes Cancer. 2011 Mar;2(3):359-72. (PMID: 21779505)
Mol Cancer. 2007 Sep 25;6:60. (PMID: 17894887)
Mol Cancer Res. 2011 Jul;9(7):856-66. (PMID: 21665939)
J Cell Physiol. 2002 Dec;193(3):287-92. (PMID: 12384981)
Int J Cancer. 2009 Dec 1;125(11):2737-43. (PMID: 19521961)
Int J Biochem Cell Biol. 2008;40(12):2707-19. (PMID: 18562239)
Int J Breast Cancer. 2012;2012:124704. (PMID: 22482058)
Mod Pathol. 2010 Mar;23(3):367-75. (PMID: 20037573)
Int J Dev Biol. 2004 Dec;48(10):1065-77. (PMID: 15602692)
Development. 2000 Apr;127(8):1715-25. (PMID: 10725247)
Endocr Relat Cancer. 2010 Jun 01;17(2):303-16. (PMID: 20071457)
Mol Cell. 2011 May 20;42(4):524-35. (PMID: 21596316)
Indian J Biochem Biophys. 2011 Aug;48(4):226-35. (PMID: 22053691)
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7016-21. (PMID: 19359480)
Cell Cycle. 2010 May;9(9):1809-18. (PMID: 20404570)
Clin Cancer Res. 2008 Jun 15;14(12):3651-6. (PMID: 18559577)
Am J Pathol. 1999 Mar;154(3):665-70. (PMID: 10079243)
EMBO J. 2011 Aug 26;30(21):4500-14. (PMID: 21873975)
Genome Res. 2010 Aug;20(8):1010-9. (PMID: 20508147)
World J Urol. 2011 Jun;29(3):367-73. (PMID: 21229250)
Mod Pathol. 2009 Mar;22(3):431-41. (PMID: 19136928)
Lancet Oncol. 2008 Jan;9(1):61-72. (PMID: 18177818)
تواريخ الأحداث: Date Created: 20141230 Date Completed: 20141230 Latest Revision: 20181113
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC4377830
DOI: 10.3390/genes6010001
PMID: 25546138
قاعدة البيانات: MEDLINE
الوصف
تدمد:2073-4425
DOI:10.3390/genes6010001